Bullous Dermatosis Antibodies EQA
| Accreditation Status: | UKAS Schedule of Accreditation | ||||||||
| Date Scheme started: | 1995 | ||||||||
| Clinical Applicability: | Diagnosis of Bullous Dermatosis (SER/009) | ||||||||
| Analytes: | Dermatosis Basement Membrane and Desmosome antibodies, antiDSG-1 antibodies, anti-DSG-3 antibodies, anti-BP-180 antibodies and anti-BP-230 antibodies | ||||||||
| Units for Reporting: | Positive or Negative, U/mL, Ratio, or Titre as appropriate | ||||||||
| Samples Distributed: | Liquid format. Normal and pathological human serum | ||||||||
| Number of Distributions per year: | 6 | ||||||||
| Number of Samples per Distribution: | 1 | ||||||||
| Frequency of Distributions: | Every two months as outlined in the Distribution Schedule | ||||||||
| Schedule of Analysis: | Data entry is via the web for the submission of results. Data analysis commences 21 days after sample dispatch. Late returns are accepted and will contribute to the laboratory's cumulative performance statistics. | ||||||||
| Data Analysis: | Qualitative responses are assessed by MIscoring in relation to the designated response. | ||||||||
| Performance Scoring: | MIscoring and OMIS for all analytes for which the laboratory is registered | ||||||||
| Criteria of Performance: |
Laboratory performance is assessed over a running analytical window of 6 Distributions (12 months) The categories of performance are:
|
||||||||
| Persistent Poor Performance: |
Defined as being in the Poor Performance category for two or more successive Distributions |